Skin Cancer in Cats: Warning Signs, Diagnosis, Treatment, and Prognosis

If a cat has a persistent skin lump, a crust that will not heal, or a reddened area that is enlarging, veterinary examination is appropriate. Appearance alone cannot distinguish cancer from a cyst, infection, inflammatory disease, trauma, or benign growth. This evidence-based guide explains the main feline skin cancers, how veterinarians move from a lesion to a tissue diagnosis, why staging differs by tumor, and how treatment and prognosis depend on histologic type, location, extent and the cat's health. This article is educational and is not a substitute for veterinary diagnosis or treatment.

At a Glance: Common Feline Skin Tumours and Their Characteristics

What Is Skin Cancer in Cats?

Feline skin cancer encompasses a range of malignant neoplasms arising from the skin, subcutaneous connective tissue, or skin-associated immune cells. The most common cutaneous malignancies in cats are cutaneous squamous cell carcinoma (SCC), mast cell tumours (MCTs), and soft-tissue sarcomas (including fibrosarcomas and injection-site sarcomas) [9][11]. Less common primary skin cancers include basal cell carcinomas, adnexal tumours, and melanoma [10]. It is crucial to understand that a lump or sore on a cat's skin does not automatically mean cancer. Abscesses, eosinophilic granulomas, insect bites, cysts, and inflammatory lesions can all mimic malignant tumours. Only a veterinary examination with appropriate diagnostics can confirm the diagnosis [9].

Risk Factors for Skin Cancer in Cats

Sun Exposure

Feline cutaneous SCC is strongly linked to chronic ultraviolet (UV) light exposure, particularly in cats with white or lightly pigmented skin and sparse hair coats on the face and ears [1]. Sun damage is cumulative; lesions often appear in older cats (median age 10–12 years) who have spent years outdoors or in sunny windows [1][3]. Cutaneous SCC is distinct from oral SCC, which has different risk factors (e.g., chronic inflammation, possible viral involvement in some cases) and a far more aggressive clinical behaviour.

Breed Predisposition

Genetic susceptibility exists for certain tumour types. For example, the Siamese, Burmese, Russian Blue, and Ragdoll breeds appear to be overrepresented in feline cutaneous MCT populations compared to mixed-breed cats [8]. Siamese cats also have an increased risk of developing mast cell tumours of the skin [11]. No breed is exempt from skin cancer, however.

Age

Most skin cancers occur in middle-aged to older cats. The median age for cutaneous SCC is around 12 years [1]. Mast cell tumours typically present at a median age of 11 years (range 5 months to 19 years) [8]. Soft-tissue sarcomas can occur at any age but are more common in older animals.

Injection History

The development of soft-tissue sarcomas, particularly fibrosarcomas, at sites of previous vaccination or long-acting injection (e.g., corticosteroids, insulin, or antibiotic injections) has been well documented. These injection-site sarcomas are locally aggressive and require aggressive surgical management [9]. Any persistent mass at a previous injection site should be investigated promptly.

Warning Signs and Symptoms of Skin Cancer in Cats

The following signs warrant a veterinary consultation:

• A lump or nodule that is growing, changing shape, or ulcerating.
• A non-healing sore, crust, or scab, especially on the nose, ears, or eyelids.
• Bleeding or discharge from a skin lesion, especially when touched.
• Pigment changes (darker or lighter colour) in a previously normal skin area.
• Pain, licking, scratching, or other changes in grooming behavior at a specific site.
• Multiple lumps, especially on the head or trunk (as may occur with MCT or SCC).
• A firm, deep-seated mass that feels attached to underlying tissues (more suspicious for soft-tissue sarcoma).

Crucially, no single symptom can differentiate cancer from a benign cyst, an infected hair follicle, a granuloma, or an abscess. For example, a mast cell tumour can look exactly like an insect bite reaction. A crusty nose could be SCC, a fungal infection (dermatophytosis), or an immune-mediated disease such as pemphigus foliaceus [9][1]. This is why veterinary diagnosis is essential.

How Feline Skin Cancer Is Diagnosed: Cytology vs. Biopsy

Fine-Needle Aspiration (FNA) and Cytology

For any newly discovered skin mass, a fine-needle aspirate is often the first step. The veterinarian inserts a small-gauge needle into the lump, withdraws cells, and smears them onto a slide for examination under the microscope. Cytology can quickly identify many common tumour types, including mast cell tumours (characteristic metachromatic granules) and squamous cell carcinoma (sheets of atypical squamous cells). However, cytology has limitations: it may not distinguish between well-differentiated and poorly differentiated tumours, and it cannot reliably assess invasion or confirm a diagnosis of sarcoma, which requires tissue architecture [9].

Biopsy and Histopathology

A biopsy (either excisional, incisional, or punch) provides a full-thickness sample of the lesion. The tissue is processed, sectioned, and interpreted by a veterinary pathologist. Histopathology is the gold standard for diagnosis and provides critical information: tumour type, grade, margin assessment (how completely it was removed), mitotic index (rate of cell division), and presence of invasion. This information is essential for staging and treatment planning [9][7][8].

Staging

Staging describes local extent and possible spread, but there is no single staging package for every feline skin tumor. After the histologic diagnosis and physical examination, a veterinarian selects tests that can change the treatment decision. Depending on tumor type and findings, these may include:

• Complete blood count and serum chemistry to assess overall health and organ function.
• Thoracic imaging when the diagnosed tumor has meaningful pulmonary metastatic potential.
• Abdominal imaging or sampling when tumor biology or clinical findings raise concern for visceral disease.
• Regional lymph-node aspiration or biopsy based on drainage anatomy and tumor behavior; normal size does not always exclude metastasis, and enlargement does not prove it.
• For cutaneous SCC, the tumour is staged based on diameter, depth of invasion, and presence of lymph node or distant metastases [3][5].

Types of Feline Skin Cancer and Their Specific Features

Cutaneous Squamous Cell Carcinoma

Cutaneous SCC is the most common feline skin malignancy and is overwhelmingly associated with sun exposure. The typical presentation is multiple, slowly progressive, crusted, or ulcerated lesions on the nasal planum, pinnae, eyelids, or other sparsely haired, lightly pigmented areas [1]. These lesions often start as superficial reddened areas (actinic keratosis) and may bleed easily when bumped.

Cutaneous SCC is distinct from oral SCC. Oral SCC in cats is a highly aggressive, locally invasive tumour of the oral cavity (often under the tongue or on the tonsils) that is not UV-related and carries a much poorer prognosis. Treatment of oral SCC is beyond the scope of this article.

Diagnosis: Cytology of a superficial scraping may show atypical squamous cells, but definitive diagnosis requires biopsy (to rule out other causes of chronic crusting and to assess depth of invasion) [1].

Staging: Depth, diameter, anatomic site, multiplicity, local tissue involvement and evidence of spread all matter. Published studies use different eligibility and staging definitions, so a stage label should be interpreted with the specific tumor site and protocol rather than converted into a universal prognosis [1][3][5].

Treatment options:

• Surgery: Small, discrete lesions on the ear tips or eyelids can be removed with acceptable cosmetic results (e.g., pinnectomy, wedge resection) [1].
• Photodynamic therapy (PDT): A photosensitizer is injected intravenously, and after a few hours the lesion is exposed to light of a specific wavelength. PDT has shown high response rates (84% overall response with complete remission in 61% of cases) in non-invasive SCC, with mean progression-free intervals over 3 years [5]. However, invasive tumours do not respond as well [4][5].
• Electrochemotherapy (ECT): Bleomycin is injected directly into the tumour followed by electric pulses that permeabilize cell membranes, improving drug uptake. In a small study of 9 cats, 77.7% had complete remission lasting up to 3 years [2].
• Radiation therapy: Hypofractionated radiation (large doses given weekly) can achieve complete response in up to 62.5% of T1 tumours but is less effective for advanced stages [3].
• Cryotherapy: Freezing superficial lesions can be effective for small, well-defined SCCs [1].
• Systemic therapy: NSAIDs (e.g., piroxicam) have been used palliatively but are not standard of care and lack robust feline data.

Cutaneous Mast Cell Tumours (MCT)

Mast cell tumours in cats are the second most common skin tumour. They arise from mast cells, which are part of the immune system. Feline cutaneous MCTs are biologically different from canine MCTs: they are more often benign but can still be malignant.

Presentation: MCTs appear as single or multiple, well-circumscribed, raised, sometimes red or pink nodules. They may be alopecic or ulcerated. A sudden increase in size after trauma or manipulation (due to mast cell degranulation) is common. The head is a frequent site in younger cats, while the trunk is more common in older cats [8]. Some MCTs are associated with significant secondary inflammation and can be mistaken for an insect bite reaction.

Diagnosis: FNA and cytology are often diagnostic because mast cells contain characteristic purple granules. However, histopathology (including special stains) is needed for grading and prognosis [7].

Prognostic factors: Mitotic activity and histologic pattern provide useful prognostic information, while multiplicity, recurrence and possible systemic involvement add clinical context [7][8]. Thresholds must be interpreted using the pathologist's method and the study in which they were validated; a number copied from a paper is not a stand-alone prognosis for an individual cat.

Treatment: Surgical excision is commonly used for a resectable cutaneous MCT. Histopathology then helps determine whether observation, additional local treatment or further staging is reasonable. Many solitary, well-differentiated tumors have favorable outcomes, but no margin or histologic feature guarantees cure. Evidence for radiation and systemic drugs in feline cutaneous MCT is much thinner than the canine literature, so specialist recommendations should identify the feline evidence and treatment goal [7][8][11].

Soft-Tissue Sarcomas (including Injection-Site Sarcomas)

Soft-tissue sarcomas are a group of mesenchymal tumours (fibrosarcoma, peripheral nerve sheath tumour, myxosarcoma, etc.) that arise from connective tissue. They are locally invasive and have a high tendency to recur after conservative excision [9].

Injection-site sarcomas are a subset that develop at a previous injection site, usually months to years after the injection. Vaccination against FeLV, rabies, and other vaccines have been implicated. Any persistent mass at a vaccination or injection site should be investigated.

Diagnosis: Deep incisional biopsy is essential. Staging (CT or MRI) may be needed to assess local extension before planning surgery.

Treatment: The first operation should be planned from biopsy and imaging rather than treated as a casual “lump removal.” Injection-site sarcomas can extend microscopically beyond the palpable mass, so surgical boundaries and the deep plane are selected by the surgeon for the individual location. Limb amputation or body-wall resection may be considered in selected cases. Radiation and systemic therapy decisions belong to an oncology plan; results from SCC electrochemotherapy studies cannot be generalized to every sarcoma [2][9].

Other Skin Cancers

• Basal cell tumours are usually benign in cats but can be locally aggressive.
• Apocrine gland adenocarcinomas are rare but malignant.
• Melanoma can occur on the skin (often on the head) but is less common than in dogs.
• Epitheliotropic lymphoma (mycosis fungoides) presents as diffuse erythema, scaling, and plaques.

Treatment Overview

The treatment plan depends on the specific tumour type, stage, location, number of lesions, and the individual cat's health status. Below is a summary of evidence-based local treatments. Do not attempt any home treatment, including applying human sunscreen or antibiotic creams, without veterinary approval. Some treatments can worsen the condition or delay diagnosis.

Surgery

Surgery is the most commonly used treatment for feline skin cancer, especially for solitary, resectable lesions. A clean surgical margin (tumour-free) is critical for preventing recurrence. The required margin width varies by tumour type; it is generally wider for sarcomas and narrower for superficial SCC or benign MCT. No universal margin can be quoted, as it depends on histology and location. Surgery may be combined with other therapies if margins are incomplete.

Photodynamic Therapy (PDT)

PDT is particularly useful for superficial SCC, especially when surgical excision would be disfiguring (e.g., nasal planum). The cat receives a photosensitizer (e.g., liposomal mTHPC) intravenously, then a diode laser at 652 nm is applied to the lesion area 4–6 hours later. Overall response rates are high for non-invasive tumours, but large and invasive tumours respond poorly [5]. PDT may also be used after debulking surgery to prevent recurrence [4].

Electrochemotherapy (ECT)

ECT combines local or intratumoral chemotherapy (bleomycin) with electrical pulses that increase cell membrane permeability. This technique has been used for feline cutaneous SCC with promising results (complete response 77.7% in one study) [2]. Minimal side effects are reported (mild erythema). ECT may be a good option for owners seeking a non-surgical approach for larger or multiple SCC lesions.

Radiation Therapy

Radiation is used when surgery is not feasible or as an adjunct after incomplete excision. For feline SCC, hypofractionated protocols (e.g., 4 weekly fractions of 7.6–10 Gy) have shown response rates of 52%, but complete response is better for T1 tumours [3]. Side effects include temporary skin erythema, epilation, and conjunctivitis (if near the eye). MCT and soft-tissue sarcoma also respond to radiation.

Cryotherapy

Cryotherapy (freezing with liquid nitrogen) is a simple, low-cost method for small, superficial SCC lesions (especially on ear tips). It is less effective for deeper tumours. Studies are limited, but it can be successful for carefully selected cases [1].

Photodynamic Therapy and Other Local Treatments

PDT, cryotherapy, and topical 5-fluorouracil (rarely used now due to toxicity) are other options for very superficial lesions. Do not use over-the-counter wart removers or human anti-fungal creams on cat lesions; they can be toxic or ineffective.

Prognosis Variability

The prognosis for cats with skin cancer varies widely depending on the tumour type, stage, and treatment.

• Cutaneous SCC: Small, superficial lesions are generally more controllable than deeply invasive lesions. Surgery, radiation, PDT and cryotherapy studies enrolled different stages and sites, so their survival or response estimates should not be compared as though the populations were interchangeable [1][3][5].
• Mast cell tumour: Many solitary, well-differentiated cutaneous MCTs have a favorable course after excision, while higher mitotic activity, atypical histology, recurrence or systemic involvement can worsen outlook [7][8].
• Soft-tissue sarcoma: Local control depends heavily on anatomic extent, the first surgical plan and histologic margins. An infiltrative tumor removed without an oncologic plan has a greater risk of local recurrence; wider planned treatment can improve control but does not guarantee cure [9].

Prevention and UV Risk Reduction

• Limit sun exposure during peak hours (10 a.m.–4 p.m.), especially for white or light-colored cats with thin facial hair.
• Ask a veterinarian before using sunscreen. Formulation and grooming exposure matter, and a product safe for human skin is not automatically safe when a cat licks it.
• Provide indoor enclosures with UV-protective film on windows.
• Regular skin checks by the owner and annual veterinary exams help catch lesions early.
• Monitor injection sites using the 3-2-1 rule: arrange assessment if a mass persists for three months, is larger than two centimeters, or is still enlarging one month after injection [9].

Key Points to Remember

• A skin lump or sore does not equal cancer. Only a veterinarian can diagnose.
• Biopsy is the gold standard for diagnosis and grading.
• Cutaneous SCC and oral SCC are different diseases with different prognoses.
• Mast cell tumours in cats are often benign but can be malignant; mitotic index is the best predictor.
• Early detection improves outcomes for almost all skin cancers.
• Treatment options are varied and should be tailored to the individual cat.

Clinical Reasoning in the Diagnosis of Feline Skin Tumours

A veterinarian evaluating a cat with a skin lesion integrates signalment, history, and lesion characteristics to prioritize differentials. For example, a crusty, non-healing erosion on the nasal planum of a white, outdoor cat immediately raises suspicion of squamous cell carcinoma (SCC) [1]. In contrast, a solitary, raised nodule on the trunk of a Siamese cat is more consistent with a mast cell tumour (MCT) [11]. This pattern-based reasoning is essential because many common feline skin diseases mimic malignancy. Eosinophilic plaques, insect bite reactions, fungal granulomas, and sterile panniculitis can all appear as suspicious lumps [9]. A thorough history should include sun exposure, vaccination and injection timeline, travel, and any prior lesions. The veterinarian will also note whether the lesion is painful, pruritic, or rapidly changing. Such clinical clues refine the differential list but never replace cytologic or histologic confirmation. For instance, a mast cell tumour can degranulate after trauma and suddenly enlarge, mimicking an abscess [8]. Only after sampling can the diagnosis be secured.

The Owner’s Role in Early Detection and Veterinary Preparation

Owners are the first line of defense against feline skin cancer. Regular, gentle palpation of the cat’s skin, while grooming or petting, can reveal new lumps or sores. If a lesion is found, owners should document its location, size (using a ruler or coin for scale), color, shape, and any discharge. Serial photographs taken in consistent lighting over several weeks help the veterinarian assess growth rate, a key indicator of malignancy. Owners must avoid squeezing, picking, or applying any topical product to the lesion, as these actions can cause inflammation, infection, or even tumour seeding. Before a veterinary visit, gather the cat’s vaccination records, a list of all medications (including preventatives), and details of any recent injections or trauma. Prepare the cat for examination by placing it in a carrier with a familiar blanket and minimizing stress during car travel. At the appointment, be ready to describe when the lesion first appeared, how it has changed, and whether the cat has shown any behavioral changes such as hiding, decreased appetite, or excessive licking. Asking targeted questions, such as “Will a biopsy be needed?” or “What is the chance this is benign?”, helps owners understand the next steps.

Diagnostic Workflow: From Initial Presentation to Definitive Diagnosis

The diagnostic pathway for a feline skin mass follows a logical sequence. The first step is a fine-needle aspirate (FNA) and cytology. This can be performed in the examination room with minimal restraint and often yields a rapid diagnosis for mast cell tumours, which exfoliate abundant granulated mast cells [7]. For SCC, cytology may show atypical squamous cells, but false negatives occur because superficial crusts may not contain diagnostic cells [1]. When cytology is non-diagnostic or suggests a sarcoma, an incisional biopsy (using a punch or wedge) is recommended to preserve tissue architecture for histopathology [9]. Deep, fixed masses require imaging, such as ultrasound or computed tomography (CT), to map the tumour’s extent and plan wide surgical excision [9]. For injection-site sarcomas, CT is especially valuable to assess involvement of underlying muscle and bone. After biopsy, immunohistochemistry can refine prognosis. In feline MCT, high KIT (CD117) immunoreactivity and a high mitotic index (>5 per 10 high-power fields) identify tumours at greater risk of aggressive behavior [7][8]. Staging (thoracic radiographs, abdominal ultrasound, lymph node aspiration) is performed before definitive treatment, because metastases change management and prognosis.

Understanding the Evidence: Strengths and Limitations of Key Studies

The evidence underlying feline skin cancer management is derived largely from small, retrospective studies with inherent limitations. For example, the photodynamic therapy (PDT) research by Flickinger et al. reported a median overall survival exceeding 40 months for cats with non-invasive SCC, but the study included only 31 cats and lacked a control group receiving no treatment [5]. Similarly, the electrochemotherapy study by Spugnini et al. showed a 77.7% complete response rate, yet enrolled just nine cats, and follow-up was less than three years for some animals [2]. The hypofractionated radiation study by Cunha et al. demonstrated a 62.5% complete response for T1 tumours, but the sample size was 16 cats, and toxicity was not systematically recorded [3]. For MCT, the large UK-based retrospective study by Melville et al. provided robust survival data from 88 cats, but it was retrospective and relied on records from multiple centers, introducing variability in histologic interpretation [8]. The prognostic value of mitotic index in feline MCT was confirmed by Sabattini and Bettini in a smaller, single-center study [7]. These limitations mean that treatment recommendations are often based on modest evidence, and clinical decisions must be individualized. Owners should be aware that “proven” therapies may have incomplete data and that outcomes can vary widely between cats.

Prognostic Factors and Long-Term Monitoring

Beyond tumor type and stage, anatomic site, depth, histologic pattern, mitotic activity, lymphovascular invasion, margins, treatment feasibility and the cat's overall health can affect outcome. The relevant factors differ by tumor: local invasion is central for cutaneous SCC, validated histologic features help stratify MCT, and the surgical field is especially important for infiltrative sarcoma [1][7][8][9]. Follow-up should therefore be prescribed for the individual diagnosis rather than defaulting every cat to the same imaging and recheck calendar. Owners should report a new lump, persistent crust, change in the operative scar, unexplained pain, appetite loss or other concerning change; the veterinarian decides whether examination, sampling or imaging is the useful next step.

Prevention Strategies Beyond Sun Protection

While limiting intense UV exposure can reduce a known risk for solar-associated SCC, not every feline skin cancer is preventable. Injection-site recommendations focus on giving only indicated injections, recording the exact site, avoiding the interscapular region, and choosing sites that preserve future treatment options if a rare sarcoma develops. Evidence comparing vaccine formulations and sarcoma risk is not strong enough to promise that one formulation eliminates risk. Owners and veterinarians should use the full 3-2-1 rule rather than waiting only for three months. Nutritional supplements have not been shown to prevent feline skin cancer. Regular inspection remains useful for finding change early, particularly on the pinnae, eyelids and nasal planum of lightly pigmented cats, but “early” does not mean owners should freeze, medicate or remove a lesion before tissue diagnosis.

Special Populations: Considerations for Young, Old, and Immunocompromised Cats

Special clinical scenarios require tailored decisions rather than different diagnostic standards. A mass in a young cat still needs sampling; age does not prove inflammation or a virus-associated sarcoma. In an older cat, kidney, thyroid, cardiac or other disease may change anesthesia and treatment planning, but chronological age alone does not determine whether surgery is appropriate. Pre-anesthetic evaluation and expected quality of life are considered alongside tumor control. Immunosuppression can alter wound healing and infection risk, yet it should not be used to infer a specific tumor type without pathology. Breed associations reported for feline cutaneous MCT may adjust clinical suspicion, but any new nodule in any breed can be benign or malignant. Cytology or biopsy, rather than breed, supplies the diagnosis [8][11].

Mapping a Lesion Before Sampling or Surgery

Good documentation begins before the lesion is disturbed. Record the anatomic site precisely, measure at least two dimensions with a ruler, and photograph it with a scale in consistent lighting. Note whether it is superficial or subcutaneous, freely movable or fixed, intact or ulcerated, solitary or one of several lesions. A body map helps distinguish a genuinely new mass from a previously sampled one. For an injection-site mass, collect dates and locations of vaccines, long-acting medications, fluids, microchips and other injections without assuming that temporal association proves cause.

Do not repeatedly squeeze, lance or apply caustic products to a mass. Manipulation can create hemorrhage and inflammation that obscure its original appearance. A superficial crust should not be peeled off before examination merely to “see underneath.” If the cat licks or traumatizes the site, the veterinarian may recommend a protective strategy while diagnostics are arranged. Owners can provide photographs and measurements, but home monitoring is not a substitute for sampling a persistent, enlarging, ulcerated or otherwise concerning lesion.

The biopsy route should preserve future treatment options. An excisional biopsy—removing the whole mass at the first procedure—may be sensible for a small, mobile lesion when adequate treatment margins can be achieved without compromising a later operation. It may be a poor choice for a large, fixed or suspected sarcoma because an unplanned incision and contaminated tissue plane can make definitive surgery more difficult. An incisional or punch biopsy removes a representative portion for diagnosis while leaving the definitive treatment field to be planned. The veterinarian chooses the path and orientation so the biopsy tract can be removed with the tumor if needed.

Reading the Pathology Report

The pathology report is more than a benign-versus-malignant label. It names the tumor or differential diagnosis, describes cellular features and may comment on mitoses, invasion, lymphatic or vascular involvement, necrosis and surgical margins. Which features are prognostic depends on the tumor. A mitotic count used in a feline mast-cell study should not be imported into a sarcoma or SCC decision. Likewise, “low grade” does not mean a mass cannot recur locally, and “malignant” does not tell an owner how quickly it will progress without the site, stage and completeness of treatment.

Margin language requires context. “Tumor does not extend to the examined edge” describes the submitted sections; it is not a guarantee that no cell remains anywhere in the patient. The measured closest margin, tissue shrinkage, sampling approach, tumor growth pattern and whether the surgeon's intended anatomic barrier was included all influence interpretation. A narrow but histologically complete margin may be handled differently for an indolent cutaneous MCT than for an infiltrative sarcoma. Ask whether the report supports monitoring, wider re-excision, radiation consultation or another action for this specific tumor.

Sometimes the initial report is descriptive rather than definitive. Special stains, immunohistochemistry, deeper sections or review by a pathologist with relevant expertise may refine the classification. That uncertainty should be resolved before committing to a treatment whose success depends on histology. If the clinical behavior and pathology seem discordant—for example, an aggressively recurrent mass described as bland—the veterinarian may request review rather than assuming one source must be correct.

Treatment Planning Is Tumor-Specific

For a small solar-associated SCC on an ear tip, surgery, cryotherapy, radiation or photodynamic therapy may each be reasonable depending on depth, site and available expertise [1][3][5]. For a nasal-planum lesion, preservation of function and local control must be balanced. A response percentage from a selected early-stage study cannot predict an individual cat with deeper invasion. The owner should ask whether the goal is cure, durable local control, reduction of symptoms or palliation, and what evidence applies to the cat's stage.

For a cutaneous MCT, cytology may quickly identify mast cells, but histopathology and the clinical pattern determine whether local excision is likely to be sufficient [7][8]. Multiple nodules do not automatically prove systemic mast-cell disease, and a solitary lesion does not guarantee indolent behavior. Further staging is chosen when histology, examination or systemic signs make it useful. Treatment recommendations should explain which finding would change the plan.

For a suspected injection-site or other infiltrative sarcoma, the first definitive surgery offers the best opportunity for local control. Cross-sectional imaging may reveal extension not appreciated on palpation and help a surgeon plan a resection. A prior “shell-out” procedure can leave microscopic disease through a broader field. Referral before the first large excision is therefore not an admission that treatment is impossible; it is an effort to preserve options. Radiation or systemic therapy may be discussed before or after surgery based on margins, location, tumor type and institutional expertise.

Follow-Up Without a Universal Calendar

There is no evidence-based schedule that fits every feline skin cancer. Follow-up intensity should reflect recurrence pattern, metastatic risk, treatment, pathology and the cat's other conditions. A superficial SCC treated locally may need close inspection of both the treated site and other sun-exposed areas. A higher-risk MCT may prompt examination of nodes or abdominal organs when clinically justified. A sarcoma plan emphasizes careful palpation and imaging of the operative field, with distant staging when tumor biology warrants it.

Owners can examine the treated area and the rest of the skin on a schedule agreed with the veterinarian. Photographs help compare a scar or pigmented region over time. New swelling, ulceration, discharge, pain, fixation or rapid change deserves earlier review rather than waiting for the next routine appointment. Conversely, an unchanged scar should not be repeatedly manipulated in search of recurrence. The oncology team should specify what to monitor, when rechecks are expected and which signs justify urgent contact.

Quality of life remains part of follow-up. Appetite, grooming, mobility, social interaction, sleep, pain and tolerance of repeated visits can matter as much as a measurement on imaging. When cure is unlikely, palliative care can target discomfort, infection, bleeding or interference with eating and movement. A palliative goal is still an active treatment goal, but it should be described honestly and reassessed as the disease changes.

Frequently Asked Questions

1. Can a cat survive skin cancer?

Yes, many cats survive skin cancer, especially when detected early and treated appropriately. For early-stage squamous cell carcinoma and low-grade mast cell tumours, long-term survival is common.

2. What are the first signs of skin cancer in cats?

The earliest signs are a persistent scab, crust, or sore that does not heal over weeks, especially on the ears, nose, or eyelids. A new lump or nodule that grows, changes colour, or bleeds is also a warning sign.

3. Is feline skin cancer painful?

Some skin cancers can be painful, especially if ulcerated, infected, or involve deeper tissues. Cats may groom the area excessively, show decreased appetite, or become withdrawn if pain is present.

4. How is skin cancer diagnosed in cats?

A veterinarian will perform a fine-needle aspirate (cytology) as a first step. A biopsy (tissue sample) with histopathology is usually needed for a definitive diagnosis and to determine the tumour type and grade.

5. Can you treat skin cancer in cats without surgery?

Yes, depending on the tumour type and stage. Photodynamic therapy (PDT) and electrochemotherapy (ECT) are effective non-surgical options for some SCC lesions. Radiation and cryotherapy are also used.

6. Are skin cancers in cats caused by the sun?

Cutaneous squamous cell carcinoma is strongly linked to chronic sun exposure. Most other feline skin cancers, such as mast cell tumours and soft-tissue sarcomas, are not sun-related.

7. What is the most common skin cancer in cats?

Cutaneous squamous cell carcinoma (SCC) is the most common skin malignancy in cats, followed by cutaneous mast cell tumours (MCTs) and soft-tissue sarcomas.

8. How fast does skin cancer grow in cats?

Growth rate varies by tumour type. Soft-tissue sarcomas may grow slowly over months, while some mast cell tumours can enlarge rapidly. Squamous cell carcinoma tends to progress slowly but can become invasive over time.

Related Veterinary Guides

• What Is FIV in Cats? Transmission, Testing, Care, and Prognosis
• What Is FIP in Cats? Symptoms, Diagnosis, Treatment, and Outlook
• FeLV Vaccine for Cats: Schedule, Safety, Effectiveness, and Risk
• Is Lavender Safe for Cats? Plants, Essential Oil, Diffusers, and Exposure
• Veterinary Medicine Knowledge Hub

References

[1] Murphy S. Cutaneous squamous cell carcinoma in the cat: current understanding and treatment approaches. Journal of feline medicine and surgery. 2013. https://pubmed.ncbi.nlm.nih.gov/23603503/

[2] Spugnini EP, Vincenzi B, Citro G, Tonini G et al. Electrochemotherapy for the treatment of squamous cell carcinoma in cats: a preliminary report. Veterinary journal (London, England : 1997). 2009. https://pubmed.ncbi.nlm.nih.gov/17904882/

[3] Cunha SC, Carvalho LA, Canary PC, Reisner M et al. Radiation therapy for feline cutaneous squamous cell carcinoma using a hypofractionated protocol. Journal of feline medicine and surgery. 2010. https://pubmed.ncbi.nlm.nih.gov/20034827/

[4] Ferreira I, Rahal SC, Rocha NS, Gouveia AH et al. Hematoporphyrin-based photodynamic therapy for cutaneous squamous cell carcinoma in cats. Veterinary dermatology. 2009. https://pubmed.ncbi.nlm.nih.gov/19374724/

[5] Flickinger I, Gasymova E, Dietiker-Moretti S, Tichy A et al. Evaluation of long-term outcome and prognostic factors of feline squamous cell carcinomas treated with photodynamic therapy using liposomal phosphorylated meta-tetra(hydroxylphenyl)chlorine. Journal of feline medicine and surgery. 2018. https://pubmed.ncbi.nlm.nih.gov/29359611/

[6] Hahn KA, Panjehpour M, Legendre AM. Photodynamic therapy response in cats with cutaneous squamous cell carcinoma as a function of fluence. Veterinary dermatology. 1998. https://pubmed.ncbi.nlm.nih.gov/34644961/

[7] Sabattini S, Bettini G. Prognostic value of histologic and immunohistochemical features in feline cutaneous mast cell tumors. Veterinary pathology. 2010. https://pubmed.ncbi.nlm.nih.gov/20418469/

[8] Melville K, Smith KC, Dobromylskyj MJ. Feline cutaneous mast cell tumours: a UK-based study comparing signalment and histological features with long-term outcomes. Journal of feline medicine and surgery. 2015. https://pubmed.ncbi.nlm.nih.gov/25193279/

[9] Merck Tumors of the Skin in Cats. https://www.merckvetmanual.com/cat-owners/skin-disorders-of-cats/tumors-of-the-skin-in-cats

[10] Merck Epidermal and Hair Follicle Tumors. https://www.merckvetmanual.com/integumentary-system/tumors-of-the-skin-and-soft-tissues/epidermal-and-hair-follicle-tumors-in-animals

[11] Merck Feline Cutaneous Mast Cell Tumors. https://www.merckvetmanual.com/integumentary-system/tumors-of-the-skin-and-soft-tissues/lymphocytic-histiocytic-and-related-cutaneous-tumors-in-animals